<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42020">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107924</url>
  </required_header>
  <id_info>
    <org_study_id>1112-0211</org_study_id>
    <nct_id>NCT02107924</nct_id>
  </id_info>
  <brief_title>Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements</brief_title>
  <official_title>Use of Antibiotic Contained Calcium Sulfate Carrier in Acute Periprosthetic Infections(APPI) of Total Knee Replacements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Muldoon, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to gather information on the use of Stimulan, the surgery, and
      anitbiotics to whetether the APPI has decreased or shown improvement when compared to study
      participants who did not receive Stimulan during their revision total knee replacement
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Retention of components</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Eradication of infection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-Reactive protein (CRP)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Assessment Scores</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing use of antibiotics</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AP and lateral Radiographs of involved joint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive synovial fluid cell count</measure>
    <time_frame>pre-operative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedimentation Rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>APPI of TKR-Stimulan</arm_group_label>
    <description>Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APPI of TKR-historical</arm_group_label>
    <description>Surgery 2.4 G Tobramycin 2.0 G Vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>APPI of TKR-Stimulan</intervention_name>
    <arm_group_label>APPI of TKR-Stimulan</arm_group_label>
    <other_name>Stimulan</other_name>
    <other_name>Tobramycin</other_name>
    <other_name>Vancomycin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Total knee replacement and have developed either APPI within 28 dyas of surgery, or an
        acute onset of a hematogenous (blood-source ) infection in knee, more than 30 days after
        surgery with symptoms present less than 28 days
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APPI within 28 days of primary TKR

          -  Acute hematogenous infection within 4 weeks of symptoms

        Exclusion Criteria:

          -  Exposed prosthesis

          -  Infection occuring in revised joints

          -  Poly articular infections

          -  have allergies to tobramycin or Vancomycin

          -  previous chronic infections in or around any ipsilateral extremity trauma or implants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Muldoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Lionberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Orthopedic Group, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael P Muldoon, MD</last_name>
    <phone>858-278-8300</phone>
    <email>mpmuldoon@cox.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cary E Murphy, RN</last_name>
    <phone>858-740-4363</phone>
    <email>cary.murphy@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southwest Orthopedic Group, LLP</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David R Lionberger, MD</last_name>
      <phone>713-333-4100</phone>
      <email>dlionberger@mysurgeon.com</email>
    </contact>
    <contact_backup>
      <last_name>Payal P Talati, MPH</last_name>
      <phone>713-800-1116</phone>
      <email>ppandit@mysurgeon.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, Garvin KL, Mont MA, Wongworawat MD, Zalavras CG. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011 Nov;469(11):2992-4. doi: 10.1007/s11999-011-2102-9.</citation>
    <PMID>21938532</PMID>
  </reference>
  <reference>
    <citation>Mortazavi SM, Vegari D, Ho A, Zmistowski B, Parvizi J. Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure. Clin Orthop Relat Res. 2011 Nov;469(11):3049-54. doi: 10.1007/s11999-011-2030-8.</citation>
    <PMID>21866421</PMID>
  </reference>
  <reference>
    <citation>Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. Infection control rate of irrigation and débridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011 Nov;469(11):3043-8. doi: 10.1007/s11999-011-1910-2.</citation>
    <PMID>21553171</PMID>
  </reference>
  <reference>
    <citation>Gardner J, Gioe TJ, Tatman P. Can this prosthesis be saved?: implant salvage attempts in infected primary TKA. Clin Orthop Relat Res. 2011 Apr;469(4):970-6. doi: 10.1007/s11999-010-1417-2.</citation>
    <PMID>20544317</PMID>
  </reference>
  <reference>
    <citation>Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ. A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res. 2010 Aug;468(8):2029-38. doi: 10.1007/s11999-010-1293-9.</citation>
    <PMID>20224958</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Michael Muldoon, M.D.</investigator_full_name>
    <investigator_title>Co-Sponsor</investigator_title>
  </responsible_party>
  <keyword>Total</keyword>
  <keyword>Knee</keyword>
  <keyword>Replacment</keyword>
  <keyword>Infection</keyword>
  <keyword>Stimulan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
